anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Oxycodone Hydrochloride
Trial phase: Phase 1
SMILES: COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314.Cl
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
Eligibility criteria:
Inclusion Criteria:

Patients with pain, Multiple dose group should enroll the Patients with cancer pain;
Patients aged >≥30 to ≤ 60 years;
Body weight ≥ 45kg, and BMI range ≥19, <24;
Karnofsky score ≥ 70;
The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;
The electrocardiogram examination results are normal;
Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test.

Exclusion Criteria:

Have hypersensitivity history to any opioids;
Have known hypersensitivity to any of compositions of the study drugs;
Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region；
Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;
Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal;
Patients with hypercarbia;
Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency;
Patients with alcoholism or drug abuse history;
Positive anti-HIV or syphilis antibody test result;
Patients who are pregnant, or lactating;
Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids;
Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study;
Subjects who participated in a clinical research study within one month of study entry;
Patients who are currently taking opioids.
Intervention: Oxycodone Hydrochloride
Trial phase: Phase 1
SMILES: COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314.Cl
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
Eligibility criteria:
Inclusion Criteria:

Patients with pain, Multiple dose group should enroll the Patients with cancer pain;
Patients aged >≥30 to ≤ 60 years;
Body weight ≥ 45kg, and BMI range ≥19, <24;
Karnofsky score ≥ 70;
The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;
The electrocardiogram examination results are normal;
Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test.

Exclusion Criteria:

Have hypersensitivity history to any opioids;
Have known hypersensitivity to any of compositions of the study drugs;
Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region；
Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;
Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal;
Patients with hypercarbia;
Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency;
Patients with alcoholism or drug abuse history;
Positive anti-HIV or syphilis antibody test result;
Patients who are pregnant, or lactating;
Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids;
Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study;
Subjects who participated in a clinical research study within one month of study entry;
Patients who are currently taking opioids.
Intervention: Oxycodone Hydrochloride
Trial phase: Phase 1
SMILES: COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314.Cl
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
Eligibility criteria:
Inclusion Criteria:

Patients with pain, Multiple dose group should enroll the Patients with cancer pain;
Patients aged >≥30 to ≤ 60 years;
Body weight ≥ 45kg, and BMI range ≥19, <24;
Karnofsky score ≥ 70;
The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;
The electrocardiogram examination results are normal;
Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test.

Exclusion Criteria:

Have hypersensitivity history to any opioids;
Have known hypersensitivity to any of compositions of the study drugs;
Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region；
Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;
Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal;
Patients with hypercarbia;
Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency;
Patients with alcoholism or drug abuse history;
Positive anti-HIV or syphilis antibody test result;
Patients who are pregnant, or lactating;
Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids;
Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study;
Subjects who participated in a clinical research study within one month of study entry;
Patients who are currently taking opioids.
Intervention: Oxycodone Hydrochloride
Trial phase: Phase 1
SMILES: COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314.Cl
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
Eligibility criteria:
Inclusion Criteria:

Patients with pain, Multiple dose group should enroll the Patients with cancer pain;
Patients aged >≥30 to ≤ 60 years;
Body weight ≥ 45kg, and BMI range ≥19, <24;
Karnofsky score ≥ 70;
The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;
The electrocardiogram examination results are normal;
Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test.

Exclusion Criteria:

Have hypersensitivity history to any opioids;
Have known hypersensitivity to any of compositions of the study drugs;
Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region；
Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;
Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal;
Patients with hypercarbia;
Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency;
Patients with alcoholism or drug abuse history;
Positive anti-HIV or syphilis antibody test result;
Patients who are pregnant, or lactating;
Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids;
Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study;
Subjects who participated in a clinical research study within one month of study entry;
Patients who are currently taking opioids.
Intervention: Cisplatin
Trial phase: Phase 3
ATC code: L01XA01
SMILES: Cl[Pt]Cl.N.N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Cisplatin 30mg by intrapleural given every two weeks

Cisplatin: Cisplatin 30mg,intrapleural administration,Q2W
Eligibility criteria:
Inclusion Criteria:

Patients with advanced recurrent or progressive NSCLC proven cytohistologically
Karnofsky performance status (KPS) ≥60
Life expectancy ≥ 2 months
No history of severe diseases of major organs including liver, heart, and kidney
No previous intrapleural therapy
Written informed consent

Exclusion Criteria:

Active thoracic cavity or systemic bleeding
Active pleural or systemic infection.
Known sensitivity to Bevacizumab or Cisplatin
Refusal to participate in the study.
Intervention: Dopamine
Trial phase: Phase 2
ATC code: C01CA04
SMILES: NCCc1ccc(O)c(O)c1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Treatment drug taken orally three times daily

Levodopa/carbidopa: This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
Eligibility criteria:
Inclusion Criteria:

clinical diagnosis of oculocutaneous albinism
age over 3 and weight over 25 lbs.

Exclusion Criteria:

ocular only albinism
ocular pathology other than albinism
neurologic disease, history of myocardial infarction, history of clinical depression, pregnancy
Intervention: Siponimod
Trial phase: Phase 3
ATC code: L04AA42 | L04AE03
SMILES: CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1099
Group description: Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on 2 mg BAF312 daily for a variable duration.
Eligibility criteria:
Inclusion Criteria:

Prior history of relapsing remitting MS
SPMS defined as progressive increase of disability over at least 6 months
EDSS score of 3.0 to 6.5
No relapse of corticosteroid treatment within 3 months

Exclusion Criteria:

Women of child bearing potential must use reliable forms of contraception.
Diagnosis of Macular edema during screening period
Any medically unstable condition determined by investigator.
Unable to undergo MRI scans
Hypersensitivity to any study drugs or drugs of similar class Other protocol defined inclusion/exclusion may apply.
Intervention: Sulfasalazine
Trial phase: Phase 2
ATC code: A07EC01 | G01AE10
SMILES: O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: 1 g oral twice daily for 2 weeks

Sulfasalazine
Eligibility criteria:
Inclusion Criteria:

Painful neuropathy
Michigan Neuropathy Screening Instrument score of 3 or greater
no obvious alternative explanation for neuropathy
average baseline pain > 4/10

Exclusion Criteria:

other severe pain
anticipated difficulty weaning off medications
past or current psychiatric disorder as determined by Mini International Neuropsychiatric Interview
medical contraindication to sulfasalazine
not proficient in English (due to heavy use of questionaires)
pregnant or breast feeding women
Intervention: Pentafluoropropane
Trial phase: Phase 4
SMILES: FC(F)CC(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.

Vapocoolant: See associated Arm Description
Eligibility criteria:
Inclusion Criteria:

Greater than or equal to 18 years old
Able to consent
Has cutaneous abscess less than or equal to 2 centimeters requiring incision and drainage in the Emergency Department

Exclusion Criteria:

Less than 18 years old
Unable to consent
Pregnant or breastfeeding
Prisoner or in police custody
Known sensitivity to vapocoolant or lidocaine
Cold hypersensitivity
Chronic steroid use
Peripheral neuropathy
Diabetes
HIV
Malignancy
Immunosuppressive state
Sickle cell disease
Sarcoidosis
Abscess greater than 2 centimeters in any dimension
Abscess requiring procedural sedation and analgesia for incision and drainage, or further intervention outside the Emergency Department
Abscess located on the hands, feet, face, or perineal areas
Pilonidal cyst
hidradenitis suppurativa
Not a good candidate per attending physician
Intervention: Goserelin Acetate
Trial phase: Phase 4
SMILES: CC(=O)O.CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 61
Group description: After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.

Zoladex: after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
Eligibility criteria:
Inclusion Criteria:

laparoscopical vaporization of endometriosis
1,2, 3e IVF cycle
endometriosis stage I and II
younger than 38 years

Exclusion Criteria:

endometriosis cysts
uterine pathology
endocrinological diseases and problems
Intervention: Buparlisib
Trial phase: Phase 2
SMILES: Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: DLBCL
Eligibility criteria:
Inclusion Criteria:

Patient had a histologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma, or diffuse large B cell lymphoma.
Patient had relapsed or refractory disease and received at least one prior therapy.
Patient with diffuse large B cell lymphoma had received or was ineligible for autologous or allogeneic stem cell transplant.
Patient had at least one measurable nodal lesion (≥2 cm) according to Cheson criteria (Cheson 2007). In case where the patient had no measurable nodal lesions ≥ 2 cm in the long axis at baseline, then the patient must have had at least one measurable extra-nodal lesion.
Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Patient had adequate bone marrow and organ function.

Exclusion Criteria:

Patient had received previous treatment with PI3K inhibitors
Patient had evidence of graft versus host disease (GVHD).
Patient had active or history of central nervous system (CNS) disease.
Patient had a concurrent malignancy or had a malignancy within 3 years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer).
Patient had a score ≥ 12 on the PHQ-9 questionnaire.
Patient had a GAD-7 mood scale score ≥ 15.
Pregnant or nursing women
Patient who did not use highly effective contraception methods to avoid becoming pregnant or conceiving offspring.
Intervention: Buparlisib
Trial phase: Phase 2
SMILES: Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: MCL
Eligibility criteria:
Inclusion Criteria:

Patient had a histologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma, or diffuse large B cell lymphoma.
Patient had relapsed or refractory disease and received at least one prior therapy.
Patient with diffuse large B cell lymphoma had received or was ineligible for autologous or allogeneic stem cell transplant.
Patient had at least one measurable nodal lesion (≥2 cm) according to Cheson criteria (Cheson 2007). In case where the patient had no measurable nodal lesions ≥ 2 cm in the long axis at baseline, then the patient must have had at least one measurable extra-nodal lesion.
Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Patient had adequate bone marrow and organ function.

Exclusion Criteria:

Patient had received previous treatment with PI3K inhibitors
Patient had evidence of graft versus host disease (GVHD).
Patient had active or history of central nervous system (CNS) disease.
Patient had a concurrent malignancy or had a malignancy within 3 years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or non-melanomatous skin cancer).
Patient had a score ≥ 12 on the PHQ-9 questionnaire.
Patient had a GAD-7 mood scale score ≥ 15.
Pregnant or nursing women
Patient who did not use highly effective contraception methods to avoid becoming pregnant or conceiving offspring.
Intervention: CALCIPOTRIENE
Trial phase: Phase 2 | Phase 3
ATC code: D05AX02 | D05AX52
SMILES: C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 33
Group description: The Calcipotriene Cream supplied as 1g daily use individual tubes used 2x/day (once in the morning and once in the evening) for 12 weeks.

Calcipotriene: 1g daily BID
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older, of either gender and any racial/ethnic group
Subjects must have clinically evident mild to moderate acne vulgaris of the facial area, IGA scale, grade 2-4
Subjects must understand and sign the informed consent prior to participation
Subjects must be in generally good health
Subjects must be able and willing to comply with the requirements of the protocol

Exclusion Criteria:

Oral retinoid use within twelve months of entry into the study
Systemic acne therapies (oral antibiotics) within 30 days of entry into the study
Topical acne therapies (retinoids, antibiotics) within 14 days of entry into the study
Non-compliant patients
Pregnant or nursing women
Subjects with a significant medical history or concurrent condition that the investigator(s) feel is not safe for study participation
Subjects with hypercalcemia (hyperparathyroidism, kidney disease)
Subjects who cannot avoid excessive exposure to either natural or artificial sunlight.
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 57
Group description: The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended for OfirmevTM administration.

Acetaminophen
Eligibility criteria:
Inclusion Criteria:

Patients 30-75 years of age weighing ≥55 kg scheduled for elective total hip arthroplasty performed under general anesthesia will be included. As determined by the anesthesia team assigned to the case, eligible patients will also be assigned ASA physical status of I, II, or III and deemed capable of reporting their perceived pain using numeric pain scales and capable of operating a patient controlled anesthesia (PCA) device.

Exclusion Criteria:

Exclusion criteria include known allergy, hypersensitivity, or contraindication to acetaminophen, history of alcohol or drug abuse, prisoners, emergency THAs, patients with chronic malnutrition or a body mass index (BMI) < 18 kg/m2 and non-English speaking patients. Additional exclusion criteria include impaired liver function defined as AST and ALT each ≥ twice normal limits and renal dysfunction (creatinine >2.0 mg/dl).
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.

Acetaminophen
Eligibility criteria:
Inclusion Criteria:

Patients 30-75 years of age weighing ≥55 kg scheduled for elective total hip arthroplasty performed under general anesthesia will be included. As determined by the anesthesia team assigned to the case, eligible patients will also be assigned ASA physical status of I, II, or III and deemed capable of reporting their perceived pain using numeric pain scales and capable of operating a patient controlled anesthesia (PCA) device.

Exclusion Criteria:

Exclusion criteria include known allergy, hypersensitivity, or contraindication to acetaminophen, history of alcohol or drug abuse, prisoners, emergency THAs, patients with chronic malnutrition or a body mass index (BMI) < 18 kg/m2 and non-English speaking patients. Additional exclusion criteria include impaired liver function defined as AST and ALT each ≥ twice normal limits and renal dysfunction (creatinine >2.0 mg/dl).
Intervention: Xylitol
Trial phase: Phase 2
SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
Eligibility criteria:
Inclusion Criteria:

English fluency and basic reading and writing literacy.
Deployment to the Persian Gulf (e.g., Iraq, Kuwait, Saudi Arabia) for the purpose of Operation Desert Shield or Operation Desert Storm during the first Gulf War (1990-1991).
Meeting criteria for a diagnosis of GWI as based on the "Kansas" GWI case definition; only the Kansas case definition (from among the several currently used case definitions) can differentiate between Gulf War-deployed and non-deployed Gulf era veterans.
Meeting criteria for a diagnosis of chronic rhinosinusitis (CRS) using self-reported symptoms and based on clinical guidelines; eligible subjects will report: • sinonasal symptoms for at least 12 weeks; • a constellation of sinonasal symptoms including either two or more major factors, or 1 major and 2 minor factors (see Table 1 below), or chronic nasal purulence for 12 or more weeks; and • a moderate to severe HRQoL impact (≥ 3 points on a 0-10 Likert severity scale) as assessed by a single item question:11 "What has been the average level of your sinus symptoms daily over the past month on a 0-10 scale?" This item is consistent with eligibility criteria used in prior NI studies.
Chronic fatigue of moderate-to-severe severity defined as scoring at least 3 points on a single question (0-10 Likert scale): "What has been the average level of your daily fatigue over the past month on a 0-10 scale?"

Exclusion Criteria:

Self-reported pregnancy.
Current use of liquid NI or xylitol nasal spray; regular use is defined as 1 or more irrigations weekly for 3 consecutive weeks.
Self-reported neurological or musculoskeletal conditions that could facilitate aspiration, or patients who otherwise cannot physically perform the NI procedure.
Self-reported borderline personality disorder.
Inability or stated reluctance to reliably participate in study activities.
Severe or unstable mental health problems that would preclude safe or reliable study participation as based on an in-person evaluation by a psychiatry team; active delusional disorder, depressive disorder or alcohol/drug abuse or dependence will be a primary target of this interview using both a structured clinical interview (MINI ref) and psychiatry team evaluation.